Movement Alert｜Edwards Lifesciences Rises 3.51% in Regular Trading, CMS Releases Favorable TAVR National Coverage Decision Memo

Market Focus06-17

On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing a Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement procedures.

RBC Capital Markets had previously identified the TAVR NCD memo as a notable upcoming catalyst for Edwards Lifesciences and the broader TAVR space. RBC's physician checks suggest coverage changes could drive approximately 5% growth in national procedure volumes, with the single-operator model shift being the most impactful component for procedure efficiency, along with site-of-service expansion. Combined with the ACC/AHA guideline update, RBC sees a favorable setup for TAVR growth acceleration into 2027.

Within the Health Care Equipment sector, Abbott Laboratories rose 1.12%, Medtronic rose 1.0%, Stryker gained 0.52%, Intuitive Surgical added 0.18%, while Boston Scientific declined 0.3%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177961575?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177961575","market":"us","top_or_hot":-1,"title":"Movement Alert｜Edwards Lifesciences Rises 3.51% in Regular Trading, CMS Releases Favorable TAVR National Coverage Decision Memo","media":"Market Focus","content":"<p><p>On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing a Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement procedures.</p><p>RBC Capital Markets had previously identified the TAVR NCD memo as a notable upcoming catalyst for Edwards Lifesciences and the broader TAVR space. RBC's physician checks suggest coverage changes could drive approximately 5% growth in national procedure volumes, with the single-operator model shift being the most impactful component for procedure efficiency, along with site-of-service expansion. Combined with the ACC/AHA guideline update, RBC sees a favorable setup for TAVR growth acceleration into 2027.</p><p>Within the Health Care Equipment sector, Abbott Laboratories rose 1.12%, Medtronic rose 1.0%, Stryker gained 0.52%, Intuitive Surgical added 0.18%, while Boston Scientific declined 0.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Edwards Lifesciences Rises 3.51% in Regular Trading, CMS Releases Favorable TAVR National Coverage Decision Memo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Edwards Lifesciences Rises 3.51% in Regular Trading, CMS Releases Favorable TAVR National Coverage Decision Memo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-17 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing a Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement procedures.</p><p>RBC Capital Markets had previously identified the TAVR NCD memo as a notable upcoming catalyst for Edwards Lifesciences and the broader TAVR space. RBC's physician checks suggest coverage changes could drive approximately 5% growth in national procedure volumes, with the single-operator model shift being the most impactful component for procedure efficiency, along with site-of-service expansion. Combined with the ACC/AHA guideline update, RBC sees a favorable setup for TAVR growth acceleration into 2027.</p><p>Within the Health Care Equipment sector, Abbott Laboratories rose 1.12%, Medtronic rose 1.0%, Stryker gained 0.52%, Intuitive Surgical added 0.18%, while Boston Scientific declined 0.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1177961575","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177961575","pubTimestamp":1781626464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"动向提示|Edwards Lifesciences常规交易涨3.51%CMS发布利好TAVR全国覆盖决策备忘录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"On June 17, Edwards Lifesciences rose 3.51% in regular trading, trading at $89.31/share, with turnover of $257 million. The rally was driven by the Centers for Medicare & Medicaid Services releasing a Proposed Decision Memo for a National Coverage Determination on transcatheter aortic valve replacement procedures.RBC Capital Markets had previously identified the TAVR NCD memo as a notable upcoming catalyst for Edwards Lifesciences and the broader TAVR space. RBC's physician checks suggest coverage changes could drive approximately 5% growth in national procedure volumes, with the single-operator model shift being the most impactful component for procedure efficiency, along with site-of-service expansion. Combined with the ACC/AHA guideline update, RBC sees a favorable setup for TAVR growth acceleration into 2027.Within the Health Care Equipment sector, Abbott Laboratories rose 1.12%, Medtronic rose 1.0%, Stryker gained 0.52%, Intuitive Surgical added 0.18%, while Boston Scientific declined 0.3%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177961575","isCrawlerRequest":true}